What is BYOOVIZ™
(ranibizumab-nuna)?
ABOUT BYOOVIZ
BYOOVIZ is an FDA-approved biosimilar* to Lucentis®
(ranibizumab injection)
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.
Consider talking to your healthcare provider about BYOOVIZ if you’ve been
diagnosed with†:
†BYOOVIZ is not approved for diabetic retinopathy (DR) and diabetic macular edema (DME).
BYOOVIZ RESULTS
In a clinical trial for wet AMD, BYOOVIZ helped people achieve similar results as people receiving Lucentis, which included:
BYOOVIZ is approved for AMD, RVO, and mCNV.
You should not use BYOOVIZ if you have an infection in or around the eye or are allergic to BYOOVIZ or any of its ingredients.
The most common side effects of BYOOVIZ include:
- Increased redness in the white of the eye
- Eye pain
- Small specks (floaters) in vision
- Increased eye pressure
RECEIVING BYOOVIZ TREATMENT
BYOOVIZ is given as an injection into the eye. Preparing for your treatment can help keep you on track.
On the day of your BYOOVIZ treatment, your healthcare provider may:
- Have you read an eye chart to check the status of your vision
- Give you eye drops as needed
- Check the condition of your eye by performing routine testing
Your healthcare provider’s office staff will try to keep you as comfortable as possible throughout treatment. Things they may do include:
- Using a tool that will gently hold your eye open for cleaning and the injection
- Utilizing eye drops to numb your eye before the injection
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
BYOOVIZ 0.5 mg (0.05 mL) is administered by injection once a month (approximately 28 days). Your healthcare provider may choose an alternate administration schedule based on your specific needs.
Macular Edema Following Retinal Vein Occlusion (RVO)
BYOOVIZ 0.5 mg (0.05 mL) is administered by injection once a month (approximately 28 days).
Myopic Choroidal Neovascularization (mCNV)
BYOOVIZ 0.5 mg (0.05 mL) is initially administered by injection once a month (approximately 28 days) for up to three months. You may be retreated if needed.
FOLLOWING
BYOOVIZ
TREATMENT
Consider the following:
- Keep in close contact with your healthcare provider’s office and be sure to follow any specific instructions they give you
- Continue any drops prescribed to you by your doctor
- If your eyes are feeling sensitive, avoid driving, wear sunglasses, and rest your eyes
If you experience any of the following side effects or changes in vision, seek immediate care:
Your healthcare provider will monitor you prior to
and following each BYOOVIZ treatment.